Better Data Tracking Could Hold Key To Indication-Based Pricing Progress
Executive Summary
Indication-based pricing could become a reality with better infrastructure to track utilization data.
You may also be interested in...
Indication-Based Pricing Sparks Interest In UK
Different prices for different medical conditions treated by the same drug and tying drug prices to the benefits they deliver are some of the recommendations made by a cross-sector expert panel to improve patient access to innovative cancer medicines.
Combination Pricing Solution As Elusive As Ever
The pricing of combination therapies, particularly in oncology, remains a headache for payers and companies.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.